PRODUCT INFORMATION



VX-765 Item No. 28825

CAS Registry No.: Formal Name:	273404-37-8 N-(4-amino-3-chlorobenzoyl)-3-methyl- L-valyl-N-[(2R,3S)-2-ethoxytetrahydro- 5-oxo-3-furanyl]-L-prolinamide	
Synonym:	Belnacasan	- O
MF:	$C_{24}H_{33}CIN_4O_6$	H ₂ N H ^{-N}
FW:	509.0	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 281 nm	
Supplied as:	A crystalline solid	ö 🗼 🗌 🗡
Storage:	-20°C	
Stability:	≥2 years	I

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

VX-765 is supplied as a crystalline solid. A stock solution may be made by dissolving the VX-765 in the solvent of choice, which should be purged with an inert gas. VX-765 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of VX-765 in these solvents is approximately 30 mg/ml.

VX-765 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, VX-765 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. VX-765 has a solubility of approximately 0.1 mg/ml in a 1:9 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

VX-765 is a prodrug form of the caspase-1 inhibitor VRT-043198.¹ VX-765 (50, 100, and 200 mg/kg) inhibits LPS-induced increases in serum IL-1ß levels in mice. It also reduces oxazolone-induced ear edema and levels of IL-1 β , IL-18, and IFN- γ in ear tissue in an oxazolone-sensitized mouse model of delayed-type hypersensitivity. VX-765 reduces forepaw inflammation in a mouse model of collagen-induced arthritis in a dose-dependent manner. VX-765 (≥50 mg/kg) decreases seizure duration and the number of seizures in a mouse model of acute seizures induced by hippocampal kainic acid injection, as well as delays the onset of seizures when administered at doses of 100 and 200 mg/kg.² It also reduces the aggregated duration of epileptic activity in a mouse model of chronic epilepsy.

References

- 1. Wannamaker, W., Davies, R., Namchuk, M., et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1 β and IL-18. J. Pharmacol. Exp. Ther. 321(2), 509-516 (2007).
- 2. Maroso, M., Balosso, S., Rivizza, T., et al. Interleukin-1ß biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8(2), 304-315 (2011).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM